EPS is usually the indicator of profitability for the company.
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ)'s price to sales ratio for trailing twelve months is 4.01 and price to book ratio for most recent quarter is 1.06. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell. The average stock price target is $11.13 with 2 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Aralez Pharmaceuticals (ARLZ) reported a fourth quarter GAAP loss of $0.48 per share Monday morning, compared to the loss of $0.40 per share a year ago.
For the quarter ending 11/07/2016, The Analyst projected that the company could deliver EPS of -0.37 while the company provided its Actual EPS of -0.3 showing a difference of 0.07 Percent between the Estimated and Actual EPS. This showed the surprise of -42.3% in the last quarter earnings.
As of current trade, Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) has shown weekly downbeat performance of -32.79%.
Now we look at the Moving Averages, the 200-day is -44.38, the 50-day is -42.07 and the 20-day is -40.09. The lowest target is $57 while the high is $79. They expect $-0.34 EPS, up 15.00% or $0.06 from last year's $-0.4 per share. The company is set at a mean analysts' recommendation of 2.60.
According to 1 analysts, the Average Revenue Estimate for the current Fiscal quarter is $30.5 Million and the Low Revenue estimate is $30.5 Million, while the High Revenue estimate is $30.5 Million. Annual EPS Growth of past 5 years is -13.20%.
The Company made noteworthy progress securing payor commitments to broaden reimbursement for Yosprala by entering into rebate agreements with two large pharmacy benefit managers to reduce access barriers, which secured formulary status for Yosprala in the U.S. The Company estimates that about 80 percent of commercial lives are now covered on National Plans. The stock, after opening at $3.16, closed at $2.46 by scoring -30.31%. Analysts mean target price for Aralez Pharmaceuticals Inc.
Shares of Aralez Pharmaceuticals Inc. are presently 12.68% off the 52 week low.
In addition to Chardan Capital reporting its stock price target, a total of 4 brokers have issued a research note on the company.
On October 31, 2016, the Company completed its acquisition of the US rights to Toprol-XL and its now marketed Authorized Generic (AG).
Aralez Pharma has 52 week low of $2.05 and a 52 week high of $6.80 and has a market capitalization of $0.
While Looking at Sales Growth (Year/est), the company is now showing a percentage value of 55.2 percent. Net profit margin of the company was recorded at 0 percent, operating profit margin was 0 percent, whereas gross profit margin stands at 77 percent.
Nobilis Health Corp. (NYSE:HLTH) [Trend Analysis] pretends to be active mover, stock fell down to knees around -17.95% to traded at $1.60. Beta factor was calculated at 0.